SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.95−0.05 (-1.67%)
Close on Nov 17, 2026Market cap $268.41MP/E –Yield –
SAB Biotherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
SAB Biotherapeutics's pe ratio was 13.4× on Apr 30, 2026, against 23.6× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 13.4× | +3.9 |
| 2025 | Dec 31, 2025 | 9.5× | −4.4 |
| 2022 | Jan 31, 2022 | 13.9× | −4.8 |
| 2021 | Dec 31, 2021 | 18.6× | – |
See a number that looks wrong?